Rule 2.7, 3.10.3, 3.10.4, 3.10.5

### **Appendix 3B**

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name	of entity	
VIEN	TO GROUP LTD	
ABN		
79 00	0 714 054	
We (t	he entity) give ASX the following	information.
	t 1 - All issues ust complete the relevant sections (atta	ch sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Ordinary fully paid Shares
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	200,000
3	Principal terms of the  †securities (e.g. if options, exercise price and expiry date; if partly paid †securities, the amount outstanding and due dates for payment; if †convertible securities, the conversion price and dates for conversion)	Ordinary fully paid Shares

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?  If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	Yes
5	Issue price or consideration	\$0.15
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Exercise of unlisted options
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	28 November 2013
6c	Number of *securities issued without security holder approval under rule 7.1	Nil
6d	Number of *securities issued with security holder approval under rule 7.1A	Nil

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil	
6f	Number of *securities issued under an exception in rule 7.2	Nil	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.		
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements		
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A — complete Annexure 1 and release to ASX Market Announcements	Remaining Issue Capa - Rule 7.1 = 11, - Rule 7.1A = 8,	749,664
7	+Issue dates	30 June 2014	
	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.		
	Cross reference: item 33 of Appendix 3B.		
		Number	+Class
8	Number and *class of all *securities quoted on ASX (including the *securities in section 2 if applicable)	89,871,511	Ordinary fully paid

<sup>+</sup> See chapter 19 for defined terms.

9 Number and \*class of all \*securities not quoted on ASX (including the \*securities in section 2 if applicable)

Number	+Class
160,000	Options exercisable
	by 30.06.15 @
	\$0.40c
4,166,664	Options exercisable
	by 30/06/2015 @
	\$0.30
2,900,000	Options exercisable
	by 30/06/2015 @
0.500.000	\$0.25
3,500,000	Options exercisable
	from 01/07/2014 and expiring
	- 1
3,500,000	30/06/2016 @ \$0.40 Options exercisable
3,500,000	from 01/07/2015
	and expiring
	30/06/2017 @ \$0.60
11,839,936	Convertible Note
11,000,000	(Tranche 1) from
	01/01/2015 until
	31/12/2015 @ \$0.30
6,236,422	Convertible Note
, ,	(Tranche 2) from
	01/01/2015 until
	31/12/2015 @ \$0.33
5,555,556	Convertible Note
	(Tranche 3) from
	01/01/2015 until
	31/12/2017 @ \$0.36

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

n/a			

#### Part 2 - Pro rata issue

11	Is security holder approval required?	
12	Is the issue renounceable or non-renounceable?	
13	Ratio in which the +securities will be offered	
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

15	+Record date to determine entitlements
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
17	Policy for deciding entitlements in relation to fractions
18	Names of countries in which the entity has security holders who will not be sent new offer documents
	Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.
19	Closing date for receipt of acceptances or renunciations
20	Names of any underwriters
21	Amount of any underwriting fee or commission
22	Names of any brokers to the issue
23	Fee or commission payable to the broker to the issue
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders
25	If the issue is contingent on security holders' approval, the date of the meeting
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled

<sup>+</sup> See chapter 19 for defined terms.

#### Appendix 3B New issue announcement

27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do security holders sell their entitlements in full through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

32	of the	do security holders dispose eir entitlements (except by hrough a broker)?	
33	†lssue	e date	
		Quotation of sec	urities applying for quotation of securities
34	Type (tick o	of *securities one)	
(a)	Χ	*Securities described in Par	t 1
(b)			nd of the escrowed period, partly paid securities that become fully paid, when restriction ends, securities issued on expiry or conversion of
Entit	ies tl	hat have ticked box 3	4(a)
Addit	ional	securities forming a new	class of securities
Tick to docum		e you are providing the informat	ion or
35			y securities, the names of the 20 largest holders of and the number and percentage of additional lders
36			securities, a distribution schedule of the additional umber of holders in the categories
37		A copy of any trust deed for	the additional *securities

<sup>+</sup> See chapter 19 for defined terms.

#### Entities that have ticked box 34(b) 38 Number of \*securities for which †quotation is sought 39 +Class of +securities for which quotation is sought Do the \*securities rank equally in 40 all respects from the +issue date with an existing \*class of quoted \*securities? If the additional \*securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 41 Reason for request for quotation Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another \*security, clearly identify that other \*security) Number +Class 42 Number and +class of all \*securities quoted on ASX (including the \*securities in clause 38)

Appendix 3B Page 8 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- We warrant the following to ASX.
  - The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the 
  +securities to be quoted under section 1019B of the Corporations Act 
  at the time that we request that the +securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

(Company secretary)

Print name: Damian Wright

== == == ==

Date: 1 July 2014

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital				
Step 1: Calculate "A", the base figure from which the placement capacity is calculated				
Insert number of fully paid *ordinary securities on issue 12 months before the *issue date or date of agreement to issue	79,799,572			
<ul> <li>Add the following:         <ul> <li>Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval</li> <li>Number of partly paid +ordinary securities that became fully paid in that 12 month period</li> </ul> </li> <li>Note:         <ul> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> </ul> </li> </ul>	7,966,667 (14/02/2014) 600,000 (18/03/2014)			
It may be useful to set out issues of securities on different dates as separate line items    Continued the second of the point to the second of the se	NET.			
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	Nil			
"A"	88,366,239			

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"			
"B"	0.15 [Note: this value cannot be changed]		
<b>Multiply</b> "A" by 0.15	13,254,936		
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used			
<ul> <li>Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:</li> <li>Under an exception in rule 7.2</li> <li>Under rule 7.1A</li> <li>With security holder approval under rule 7.1 or rule 7.4</li> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>	130,000 (5/09/2013) 746,268 (12/03/2014) 369,004 (13/05/2014) 60,000 (17/06/2014) 200,000 (30/06/2014)		
"C"	1,505,272		
Step 4: Subtract "C" from ["A" x "E placement capacity under rule 7.1	3"] to calculate remaining		
"A" x 0.15 Note: number must be same as shown in Step 2	13,254,936		
Subtract "C"  Note: number must be same as shown in Step 3	1,505,272		
<i>Total</i> ["A" x 0.15] – "C"	11,749,664 [Note: this is the remaining placement capacity under rule 7.1]		

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placem	ent capacity for eligible entities	
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	88,366,239	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<i>Multiply</i> "A" by 0.10	8,836,624	
Step 3: Calculate "E", the amount of 7.1A that has already been used	of placement capacity under rule	
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A  Notes:  This applies to equity securities – not just ordinary securities  Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed  Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained  It may be useful to set out issues of securities on different dates as separate line items  "E"  Step 4: Subtract "E" from ["A" x "I placement capacity under rule 7.1/"	-	
"A" x 0.10	8,836,624	
Note: number must be same as shown in Step 2		
Subtract "E"	-	
Note: number must be same as shown in Step 3		
<b>Total</b> ["A" x 0.10] – "E"	8,836,624	
	Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.

Appendix 3B Page 12 04/03/2013